PARP inhibitorFDA-approvedSecond-line
Olaparib
How it works
Blocks the enzyme that helps repair damaged DNA, making it harder for cancer cells to grow and divide.
Cancer types
Ovarian Cancer— BRCA1/2-mutated
Pancreatic Cancer— BRCA1/2-mutated patients
Breast Cancer— BRCA1/2-mutated
Prostate Cancer— BRCA1/2-mutated
Efficacy
Olaparib has been shown to improve progression-free survival in BRCA1/2-mutated ovarian cancer patients, with a median progression-free survival of approximately 8 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| New Compound Disrupts Cancer Gene Expression | Colorectal Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Studying Olaparib in Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Olaparib Study for Patients Who Have Completed Previous Oncology Trials | Breast Cancer | phase-3 | — | Source → |
| Testing Olaparib with Radium-223 in Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Cediranib and Olaparib Combination Therapy for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing a Combination of Two Drugs for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Ovarian and Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing Cediranib and Olaparib in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing New Treatments for Women with Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing FPI-2265 and Olaparib for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Evaluating Olaparib in Chinese Patients with Advanced Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib Sensitivity in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Recurrent Ovarian and Peritoneal Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Olaparib for Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Pancreatic Cancer Treatment Trial | Pancreatic Cancer | phase-1 | — | Source → |
| Olaparib Trial for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a Combination of Two Oral Drugs for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combining SM08502 and Olaparib May Help Overcome Cancer Resistance | Ovarian Cancer | lab-study | — | Source → |
| New Treatment Options for Advanced Ovarian Cancer Patients | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Researchers Identify New Target to Enhance Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Curcumin Analogue and Olaparib Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
| TTK protein linked to resistance in ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Combining Cancer Treatments May Help Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Boosts Immune Response in Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Olaparib Monotherapy Shows Promise in Lung Cancer Treatment | Lung Cancer | meta-analysis | Olaparib monotherapy increased progression-free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. | Source → |
| Rare Skin Condition Linked to Cancer Treatment | Ovarian Cancer | observational | — | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Olaparib Therapy Side Effects in UAE Patients | Breast Cancer | observational | — | Source → |
| Olaparib vs Nonplatinum Chemotherapy in Ovarian Cancer | Ovarian Cancer | phase-3 | Overall survival with olaparib was similar to chemotherapy (median 34.9 and 32.9 months, respectively). | Source → |
| Combining drugs may improve ovarian cancer treatment | Ovarian Cancer | lab-study | The combined treatment allows a substantial dose reduction of olaparib rendering a strong synergistic effect. | Source → |
| Olaparib Maintenance Therapy Shows Promise in Ovarian Cancer | Ovarian Cancer | observational | The 1-year progression-free survival rate was 75.2% (95% CI, 63.4 to 89.2), and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). | Source → |
| Combining Cancer Drugs May Improve Treatment for Advanced Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Lung Disease Linked to Cancer Treatment | Breast Cancer | observational | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| gBRCA Testing and Olaparib in Pancreatic Cancer | Pancreatic Cancer | observational | The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). | Source → |
| Combination Cediranib and Olaparib Shows Activity in Ovarian Cancer | Ovarian Cancer | phase-2 | In platinum-sensitive ovarian cancer, the overall response rate was 77.1% and median progression-free survival was 16.4 months. | Source → |
| Olaparib Maintenance Therapy in Ovarian Cancer: Biomarker Analysis | Ovarian Cancer | phase-3 | HRD-positive patients displayed greater median PFS [17.9 months (95% CI: 14.5-22.1)] than HRD-negative patients [9.2 months (95% CI: 7.5-13.8)]. | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer: A Study at Kurume University Hospital | Ovarian Cancer | observational | The median progression-free survival was 8.9 months, and the median overall survival was 27.1 months. | Source → |
| Pancreatic Cancer Treatment Shows Promise in Rare Genetic Case | Ovarian Cancer | observational | — | Source → |
| CRABP2 May Reduce Effectiveness of Cancer Treatment Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Inhibiting FSP1 Enhances Olaparib Sensitivity in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Olaparib and CDK12-IN-3 to Treat Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Possible Cause of Cancer Treatment Resistance | Pancreatic Cancer | lab-study | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| Combining drugs may help overcome resistance to ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Measuring PARP Inhibitors in Ovarian Cancer Patients | Ovarian Cancer | lab-study | — | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.